Publication
Road to COP29: Our insights
The 28th Conference of the Parties on Climate Change (COP28) took place on November 30 - December 12 in Dubai.
Global FinTech survey report | Key findings
United Kingdom | Publication | July 2020
Financial institutions, including banks, asset/fund managers and insurers, as well as established FinTech businesses and start-ups, have been presented with major disruptive events with the advent of COVID-19 and national lockdowns, and with the impending risk of global or regional recessions.
How are financial institutions and FinTechs responding to such challenges? What role might new business models, strategic collaborations, investment and M&A, outsourcing, regulatory considerations, and the risk of litigation play in addressing such challenges?
To find out, in May and June we undertook a survey of a range of banks, asset/fund managers, insurers, established FinTech businesses, FinTech start-ups and venture capital and consulting firms across the globe.
We invite you to read the findings of the survey which cover the following subject areas:
- FinTech as a strategic priority
- New FinTech use cases
- FinTech strategic collaborations
- FinTech investment and M&A
- Outsourcing and FinTech
- Regulatory impact in relation to FinTech initiatives
- FinTech areas of potential dispute
Global head of FinTech
Email
sean.murphy@nortonrosefulbright.com
Knowledge Consultant
Email
michael.sinclair@nortonrosefulbright.com
Asia Head of FinTech and Financial Services Regulatory; Partner
Email
etelka.bogardi@nortonrosefulbright.com
T:
+65 63095455
US Head of Financial Services and Global Head of Private Wealth
Email
andrew.lom@nortonrosefulbright.com
Recent publications
Publication
The GCR Guide to Life Sciences – Merger control: Procedural issues
Miranda Cole, Julien Haverals and Emma Clarke of our Brussels/ London offices are the authors of a chapter on procedural issues in merger control that has been published in the third edition of the Global Competition Review’s The Guide to Life Sciences. This covers a number of significant procedural developments that have affected merger review of life sciences transactions.
Subscribe and stay up to date with the latest legal news, information and events . . .